logo
Plus   Neg
Share
Email

Revance Therapeutics Inc. (RVNC) Surged To A New High On Study Results

Revance Therapeutics Inc. (RVNC) announced Tuesday morning that its two Phase 3 trials of RT002 injection met their primary and all secondary endpoints in patients with Glabellar lines.

Revance Therapeutics gapped open sharply higher Tuesday, but traded in a range for the majority of the session. Shares finished with a gain of 8.75 at $34.75 on the highest volume of the year. The stock soared to a new high for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT